We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.

AusPAR: Evusheld

Australian Public Assessment Report

AusPAR

AusPAR: Evusheld [PDF, 1.67 MB]

AusPAR: Evusheld [Word, 2.69 MB]

AusPAR Attachment 1: Product Information for Evusheld [PDF, 393.68 KB]

AusPAR Attachment 1: Product Information for Evusheld [Word, 346.96 KB]

Device/Product Name

Evusheld

Active ingredients

Tixagevimab and cilgavimab

AusPAR Date

4 January 2023

Published

5 January 2023

Submission Number

PM-2021-05375-1-2 and PM-2022-03097-1-2

Submission Type

New biological entity and change in dosage and change to Product Information requiring evaluation of new data

Decision

Approved for provisional registration